Preclinical Gene Therapy Studies for Hemophilia Using Adeno-Associated Virus (AAV) Vectors

Linda B. Couto

doi:10.1055/s-2004-825630

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2004; 30(2): 161-171
DOI: 10.1055/s-2004-825630

Preclinical Gene Therapy Studies for Hemophilia Using Adeno-Associated Virus (AAV) Vectors

Linda B. Couto¹ ^, ²

¹Senior Director, Pre-clinical Research, Avigen, Inc., Alameda, California
²Current affiliation: Couto Consulting, Pleasanton, California

Abstract

Gene therapy offers a potential cure for hemophilia and several gene transfer vectors have been evaluated for their ability to treat this disease. This article reviews the studies that have been performed to evaluate the ability of recombinant adeno-associated virus (AAV) vectors to achieve safely the sustained expression of clotting factors following intramuscular, intravenous, and intrahepatic delivery to several animal models. These routes of administration are all effective in providing sustained and therapeutic levels of factor IX (FIX), although the levels vary. Intrahepatic delivery is more efficacious than intravenous administration, which is superior to intramuscular delivery. The recent development of efficient factor VIII (FVIII) expression cassettes has made AAV-based gene therapy for hemophilia A also within reach. Although no acute toxicity has been observed with any route of administration, an increased risk of antibody formation against FIX has been noted following intramuscular delivery. Biodistribution studies concluded that the vector disseminates to most tissues in a dose-dependent and time-dependent manner, but the majority of the vector resides in the targeted tissue. In addition, the risk of germline transmission has been shown to be low or absent. The relatively recent isolation of new AAV serotypes has resulted in the identification of vectors that have enhanced tropism for certain tissues. This combined with the potential of these new vectors to evade the immune response to AAV2, makes them attractive candidates for gene therapy. Although much progress has been made using AAV to treat hemophilia, there are several outstanding issues that need to be addressed. Delivery of AAV to large animals has not been reproducible, which could be due to nonoptimized delivery and/or immune responses to the vector or transgene product. In addition, a complete understanding of the biology of these vectors is required to assess their long-term safety. Solving these issues will lead to the development of a successful gene therapy product.

KEYWORDS

Adeno-associated virus - vector - factor IX - FIX - factor VIII - FVIII

Full Text

References

REFERENCES

1 Muzyczka N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol. 1992; 158 97-129
2 Xiao X, Li J, Samulski R J. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol. 1996; 70 8098-8108
3 Kessler P D, Podsakoff G M, Chen X et al.. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA. 1996; 93 14082-14087
4 Herzog R W, Hagstrom J N, Kung S H et al.. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA. 1997; 94 5804-5809
5 Nathwani A C, Davidoff A, Hanawa H, Zhou J F, Vanin E F, Nienhuis A W. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. Blood. 2001; 97 1258-1265
6 Ge Y, Powell S, Van Roey M, McArthur J G. Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX. Blood. 2001; 97 3733-3737
7 Fields P A, Kowalczyk D W, Arruda V R et al.. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol Ther. 2000; 1 225-235
8 Fields P A, Arruda V R, Armstrong E et al.. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. Mol Ther. 2001; 4 201-210
9 Evans J P, Brinkhous K M, Brayer G D, Reisner H M, High K A. Canine hemophilia B resulting from a point mutation with unusual consequences. Proc Natl Acad Sci USA. 1989; 86 10095-10099
10 Herzog R W, Yang E Y, Couto L B et al.. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med. 1999; 5 56-63
11 Herzog R W, Fields P A, Arruda V R et al.. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum Gene Ther. 2002; 13 1281-1291
12 Mauser A E, Whitlark J, Whitney K M, Lothrop Jr C D. A deletion mutation causes hemophilia B in Lhasa Apso dogs. Blood. 1996; 88 3451-3455
13 Herzog R W, Mount J D, Arruda V R, High K A, Lothrop Jr C D. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol Ther. 2001; 4 192-200
14 Manno C S, Chew A J, Hutchison S et al.. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood. 2003; 101 2963-2972
15 Snyder R O, Miao C H, Patijn G A et al.. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet. 1997; 16 270-276
16 Nakai H, Herzog R W, Hagstrom J N et al.. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood. 1998; 91 4600-4607
17 Snyder R O, Miao C, Meuse L et al.. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med. 1999; 5 64-70
18 Wang L, Takabe K, Bidlingmaier S M, Ill C R, Verma I M. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci USA. 1999; 96 3906-3910
19 Parker A, Nagy D, Vargas J et al.. In vivo performance of AAV2 vectors purified by CsCl gradient centrifugation or column chromatography. Mol Ther. 2003; 7 S390
20 Miao C H, Ohashi K, Patijn G A et al.. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. Mol Ther. 2000; 1 522-532
21 Kay M AHK, Glader B, Manno C S et al.. A phase I/II clinical trial for liver directed AAV-mediated gene transfer for severe hemophilia B. Blood. 2002; 100 (suppl) 426
22 Wang L, Nichols T C, Read M S, Bellinger D A, Verma I M. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol Ther. 2000; 1 154-158
23 Mount J D, Herzog R W, Tillson D M et al.. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood. 2002; 99 2670-2676
24 Nathwani A C, Davidoff A M, Hanawa H et al.. Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. Blood. 2002; 100 1662-1669
25 Mingozzi F, Liu Y L, Dobrzynski E et al.. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest. 2003; 111 1347-1356
26 Nakai H, Iwaki Y, Kay M A, Couto L B. Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver. J Virol. 1999; 73 5438-5447
27 Grimm D, Zhou S, Nakai H et al.. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood. 2003; 102 2412-2419
28 Chiorini J A, Yang L, Liu Y, Safer B, Kotin R M. Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J Virol. 1997; 71 6823-6833
29 Chiorini J A, Kim F, Yang L, Kotin R M. Cloning and characterization of adeno-associated virus type 5. J Virol. 1999; 73 1309-1319
30 Gao G P, Alvira M R, Wang L, Calcedo R, Johnston J, Wilson J M. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA. 2002; 99 11854-11859
31 Rutledge E A, Halbert C L, Russell D W. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol. 1998; 72 309-319
32 Xiao W, Chirmule N, Berta S C, McCullough B, Gao G, Wilson J M. Gene therapy vectors based on adeno-associated virus type 1. J Virol. 1999; 73 3994-4003
33 Duan D, Yan Z, Yue Y, Ding W, Engelhardt J F. Enhancement of muscle gene delivery with pseudotyped adeno-associated virus type 5 correlates with myoblast differentiation. J Virol. 2001; 75 7662-7671
34 Rabinowitz J E, Rolling F, Li C et al.. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol. 2002; 76 791-801
35 Chao H, Liu Y, Rabinowitz J, Li C, Samulski R J, Walsh C E. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther. 2000; 2 619-623
36 Chao H, Monahan P E, Liu Y, Samulski R J, Walsh C E. Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. Mol Ther. 2001; 4 217-222
37 Arruda V R, Schuettrumpf J, Herzog R W et al.. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood. 2003; 11 11
38 Mingozzi F, Schuttrumpf J, Arruda V R et al.. Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector. J Virol. 2002; 76 10497-10502
39 Pittman D D, Tomkinson K N, Kaufman R J. Post-translational requirements for functional factor V and factor VIII secretion in mammalian cells. J Biol Chem. 1994; 269 17329-17337
40 Burton M, Nakai H, Colosi P, Cunningham J, Mitchell R, Couto L. Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein. Proc Natl Acad Sci USA. 1999; 96 12725-12730
41 Scallan C D, Liu T, Parker A E et al.. Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII. Blood. 2003; 102 3919-3926
42 Chao H, Sun L, Bruce A, Xiao X, Walsh C E. Expression of human factor VIII by splicing between dimerized AAV vectors. Mol Ther. 2002; 5 716-722
43 Gnatenko D V, Saenko E L, Jesty J, Cao L X, Hearing P, Bahou W F. Human factor VIII can be packaged and functionally expressed in an adeno-associated virus background: applicability to haemophilia A gene therapy. Br J Haematol. 1999; 104 27-36
44 Chao H, Mao L, Bruce A T, Walsh C E. Sustained expression of human factor VIII in mice using a parvovirus-based vector. Blood. 2000; 95 1594-1599
45 Sarkar R, Xiao W, Kazazian Jr H H. A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype. J Thromb Haemost. 2003; 1 220-226
46 Couto L SC, Jiang H, Qian X et al.. Hemophilia A gene therapy in mouse and dog models using an AAV-FVIII vector. Blood. 2002; 100(suppl) 117a
47 Scallan C D, Lillicrap D, Jiang H et al.. Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector. Blood. 2003; 102 2031-2037
48 Jiang H, Patarroyo-White S, Nagy D et al.. Improved efficacy in gene therapy of Hemophilia A using an AAV6 pseudo-typed FVIII vector. Mol Ther. 2003; 7 S184-(abst)
49 Arruda V R, Fields P A, Milner R et al.. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. Mol Ther. 2001; 4 586-592
50 Summerford C, Samulski R J. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol. 1998; 72 1438-1445
51 Couto L, Parker A, Gordon J. Direct exposure of mouse sperm to high concentrations of an adeno-associated virus gene therapy vector fails to lead to germ cell transduction. Mol Ther. 2003; 7 S161 (abst)
52 Miller D G, Rutledge E A, Russell D W. Chromosomal effects of adeno-associated virus vector integration. Nat Genet. 2002; 30 147-148
53 Nakai H, Yant S R, Storm T A, Fuess S, Meuse L, Kay M A. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol. 2001; 75 6969-6976
54 Nakai H, Montini E, Fuess S, Storm T A, Grompe M, Kay M A. AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet. 2003; 34 297-302
55 Moskalenko M, Chen L, van Roey M et al.. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J Virol. 2000; 74 1761-1766
56 Parks W BD, Melnick J, Taber L, Yow M. Seroepidemiological and ecological studies of the adenovirus-associated satellite viruses. Infect Immun. 1970; 2 716-722
57 Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 1999; 6 1574-1583

Linda B CoutoPh.D.

Couto Consulting

7814 Oak Creek Dr., Pleasanton

CA 94588

Email: coutoconsulting@yahoo.com